(in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $221.12 | $193.08 | $161.71 | $67.76 |
Short term investments | ||||
Net receivables | $162.08 | $178.84 | $172.93 | $174.71 |
Inventory | $111.2 | $106.59 | $104.32 | $103.65 |
Total current assets | $519.82 | $497.22 | $459.31 | $364.75 |
Long term investments | ||||
Property, plant & equipment | $44.59 | $44.19 | $44.37 | $43.27 |
Goodwill & intangible assets | $237.23 | $248.05 | $258.52 | $267.01 |
Total noncurrent assets | $384.61 | $392.69 | $400.03 | $400.47 |
Total investments | ||||
Total assets | $904.42 | $889.91 | $859.34 | $765.22 |
Current liabilities | ||||
Accounts payable | $36.68 | $34.08 | $28.5 | $32.69 |
Deferred revenue | ||||
Short long term debt | $0.85 | $0.85 | $0.85 | $0.85 |
Total current liabilities | $145.48 | $134.35 | $122.86 | $125.83 |
Long term debt | $284.82 | $285.03 | $285.24 | $285.46 |
Total noncurrent liabilities | $301.35 | $300.85 | $302 | $299.92 |
Total debt | $285.67 | $285.88 | $286.09 | $286.31 |
Total liabilities | $446.82 | $435.2 | $424.87 | $425.74 |
Shareholders' equity | ||||
Retained earnings | -$80.13 | -$80.88 | -$90.41 | -$96.25 |
Other shareholder equity | $8.86 | $14.08 | $13.73 | $11.13 |
Total shareholder equity | $432.75 | $429.86 | $409.62 | $314.63 |
(in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Current assets | ||||
Cash | $221.12 | $53.23 | $105.3 | $12.87 |
Short term investments | ||||
Net receivables | $162.08 | $169.26 | $128.53 | $95.79 |
Inventory | $111.2 | $105.36 | $81.69 | $60.8 |
Total current assets | $519.82 | $344.26 | $321.77 | $170.32 |
Long term investments | ||||
Property, plant & equipment | $44.59 | $43.25 | $52.67 | $41.27 |
Goodwill & intangible assets | $237.23 | $279.86 | $322.01 | $192.09 |
Total noncurrent assets | $384.61 | $415.83 | $449.82 | $290.87 |
Total investments | ||||
Total assets | $904.42 | $760.09 | $771.6 | $461.19 |
Current liabilities | ||||
Accounts payable | $36.68 | $29.3 | $22.97 | $11.26 |
Deferred revenue | $0.09 | $0.08 | ||
Short long term debt | $0.85 | $0.85 | $0.85 | $13.24 |
Total current liabilities | $145.48 | $99.44 | $87.54 | $78.56 |
Long term debt | $284.82 | $285.67 | $286.52 | $172.44 |
Total noncurrent liabilities | $301.35 | $322.11 | $325.32 | $186.93 |
Total debt | $285.67 | $286.52 | $287.37 | $185.69 |
Total liabilities | $446.82 | $421.55 | $412.86 | $265.49 |
Shareholders' equity | ||||
Retained earnings | -$80.13 | -$97.29 | -$47.77 | -$4.97 |
Other shareholder equity | $8.86 | $12.17 | -$3.06 | -$11.44 |
Total shareholder equity | $432.75 | $313.69 | $333.89 | $195.7 |
(in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $131.65 | $116.55 | $106.79 | |
Cost of revenue | $53.42 | $42.28 | $37.71 | |
Gross Profit | $78.23 | $74.26 | $69.08 | |
Operating activities | ||||
Research & development | $9.87 | $7.37 | $5.92 | |
Selling, general & administrative | $44.46 | $38.76 | $36.47 | |
Total operating expenses | $69.56 | $60.88 | $58.26 | |
Operating income | $8.68 | $13.38 | $10.82 | |
Income from continuing operations | ||||
EBIT | $6.69 | $12.35 | $9.86 | |
Income tax expense | -$0.21 | -$1 | $0.73 | |
Interest expense | $5.75 | $7.1 | $7.7 | |
Net income | ||||
Net income | $1.16 | $6.25 | $1.44 | |
Income (for common shares) | $0.75 | $5.84 | $1.03 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $486.82 | $316.38 | $216.14 | $208.47 |
Cost of revenue | $181.51 | $138.78 | $100.61 | $87.16 |
Gross Profit | $305.3 | $177.6 | $115.53 | $121.32 |
Operating activities | ||||
Research & development | $34.29 | $22.32 | $11.37 | $16 |
Selling, general & administrative | $161.7 | $124.04 | $84.29 | $64.99 |
Total operating expenses | $257.06 | $208.46 | $159.16 | $137.83 |
Operating income | $48.24 | -$30.86 | -$43.64 | -$16.51 |
Income from continuing operations | ||||
EBIT | $46.81 | -$34.61 | -$44.14 | -$16.51 |
Income tax expense | $1.09 | -$14.77 | -$13.46 | -$3.41 |
Interest expense | $26.94 | $28.05 | $11.92 | $9.45 |
Net income | ||||
Net income | $18.78 | -$47.9 | -$42.6 | -$22.55 |
Income (for common shares) | $17.15 | -$49.52 | -$42.79 | -$22.55 |
(in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Net income | $1.16 | $9.94 | $6.25 | $1.44 |
Operating activities | ||||
Depreciation | $15.57 | $16.03 | $14.75 | $14.7 |
Business acquisitions & disposals | -$2.5 | -$2.81 | -$4.33 | -$0 |
Stock-based compensation | $5.62 | $5.44 | $5.25 | $4.34 |
Total cash flows from operations | $44.74 | $32.17 | $20.63 | $21.42 |
Investing activities | ||||
Capital expenditures | -$2.28 | -$1.74 | -$2.5 | -$2.35 |
Investments | ||||
Total cash flows from investing | -$4.78 | -$4.55 | -$6.83 | -$2.35 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | $1.74 | $4.91 | $81.31 | -$3.39 |
Net borrowings | -$0.75 | -$0.75 | -$0.75 | -$0.75 |
Total cash flows from financing | -$11.92 | $3.75 | $80.15 | -$4.55 |
Effect of exchange rate | ||||
Change in cash and equivalents | $28.04 | $31.37 | $93.95 | $14.52 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Net income | $18.78 | -$47.9 | -$42.6 | -$22.55 |
Operating activities | ||||
Depreciation | $61.06 | $59.65 | $47.25 | $44.64 |
Business acquisitions & disposals | -$9.64 | -$7.61 | -$105.58 | -$62.19 |
Stock-based compensation | $20.65 | $14.6 | $10.49 | $12.94 |
Total cash flows from operations | $118.96 | -$31.2 | $3.32 | $15.27 |
Investing activities | ||||
Capital expenditures | -$8.87 | -$8.13 | $0.09 | -$6.13 |
Investments | ||||
Total cash flows from investing | -$18.51 | -$15.74 | -$105.48 | -$68.32 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | $84.56 | -$0.5 | $76.18 | -$0.91 |
Net borrowings | -$3 | -$3 | $99.02 | -$0.53 |
Total cash flows from financing | $67.44 | -$5.13 | $194.59 | -$1.44 |
Effect of exchange rate | ||||
Change in cash and equivalents | $167.89 | -$52.07 | $92.43 | -$54.49 |
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
Zacks via Yahoo Finance
22 Mar 2024
|
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Zacks via Yahoo Finance
22 Mar 2024
|
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
Zacks via Yahoo Finance
21 Mar 2024
|
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
Zacks via Yahoo Finance
21 Mar 2024
|
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
Zacks via Yahoo Finance
20 Mar 2024
|
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Zacks via Yahoo Finance
20 Mar 2024
|
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
Zacks via Yahoo Finance
20 Mar 2024
|
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
Zacks via Yahoo Finance
18 Mar 2024
|
ANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 Shares
GuruFocus.com via Yahoo Finance
9 Mar 2024
|
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
Zacks via Yahoo Finance
8 Mar 2024
|
Market cap | $1.43B |
---|---|
Enterprise value | $1.49B |
Shares outstanding | 20.48M |
Revenue | N/A |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | N/A |
Revenue Q/Q | 39.71% |
Revenue Y/Y | N/A |
P/E ratio | N/A |
---|---|
EV/Sales | N/A |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | N/A |
P/B ratio | 3.37 |
Book/Share | 20.70 |
Cash/Share | 10.80 |
EPS | N/A |
---|---|
ROA | N/A |
ROE | N/A |
Debt/Equity | 1.03 |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 3.57 |
Quick ratio | 2.81 |